Plain-English translation of NCT05758532 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether changing the timing and spacing of the measles-mumps-rubella (MMR) vaccine can help protect children from infections caused by other germs and from allergic diseases like eczema. Researchers believe that giving the vaccine at different ages — and sometimes separately from other vaccines — might boost its protective effects beyond just preventing measles, mumps, and rubella. This study will compare the standard vaccine schedule used in Switzerland with three alternative schedules to see which approach works best.
Recent research suggests that the MMR vaccine may have broader protective effects on a child's immune system beyond preventing the three diseases it targets. This trial exists to find out whether adjusting when and how the vaccine is given could help reduce the number of other infections children catch and lower the risk of developing allergies — ultimately giving children stronger overall protection.
You likely qualify if…
You likely don't qualify if…
If you join this trial, your child will be randomly assigned to receive the MMR vaccine on one of four different schedules — either the standard Swiss schedule (at 9 and 12 months) or one of three modified schedules that change when the two doses are given (ranging from 6 to 13 months). Some schedules give the vaccine alongside other routine vaccines, while others space them apart. Your child will receive the same safe vaccine used in regular care; only the timing changes. Throughout the study, researchers will monitor your child's health, track any infections or allergic reactions, and may do blood tests to understand how the vaccine is affecting the immune system.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Switzerland
Phase
Post-approval monitoring
Sponsor
Laure Pittet, MD-PhD
Enrollment target
~500 participants
Started
March 2023
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
6 Months – 6 Months
Last updated on clinicaltrials.gov in May 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Laure F Pittet, MD-PhD
University Hospitals of Geneva
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.